<SUBMISSION>
<ACCESSION-NUMBER>0001144204-05-019308
<TYPE>6-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20050620
<FILING-DATE>20050620
<DATE-OF-FILING-DATE-CHANGE>20050620
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>pSivida LTD
<CIK>0001314102
<ASSIGNED-SIC>3826
<IRS-NUMBER>000000000
<STATE-OF-INCORPORATION>C3
<FISCAL-YEAR-END>0630
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>6-K
<ACT>34
<FILE-NUMBER>000-51122
<FILM-NUMBER>05904569
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
<PHONE>61 8 9226 5099
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v020379.htm
<TEXT>
<HTML><HEAD>
<TITLE>
Unassociated Document
</TITLE>
<!-- Licensed to: vintage-->
<!-- Document Created using EDGARIZER HTML -->
<!-- Copyright 2004 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</HEAD><BODY id=38 bgColor=#ffffff>
<DIV><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><STRONG>SECURITIES
AND EXCHANGE COMMISSION</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>Washington,
D.C. 20549</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><STRONG>FORM
6-K</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">REPORT OF
FOREIGN ISSUER</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to Rule 13a-16 or 15d-16 of</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
Securities Exchange Act of 1934</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>For
the month of June 2005</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>Commission
File Number 000-5112</STRONG>2</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>pSivida
Limited</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
of registrant&#8217;s name into English) </FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level 12
BGC Centre</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28 The
Esplanade</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Perth WA
6000</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
of principal executive offices)</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Indicate
by check mark whether the registrant files or will file annual reports under
cover Form&nbsp;20-F or Form&nbsp;40-F). </FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form 20-F
<FONT face=Wingdings>x</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F <FONT
face=Wingdings>o</FONT></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1):</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7):</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark whether the registrant by furnishing the information contained in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934.</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes <FONT
face=Wingdings>o</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No <FONT
face=Wingdings>x</FONT></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If "Yes"
is marked, indicate below the file number assigned to the registrant in
connection with Rule&nbsp;12g3-2(b): 82- ___. </FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>SIGNATURE
</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant,
pSivida Limited, has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized. </FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:
June 20, 2005</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<TABLE cellSpacing=0 cellPadding=0 width="100%" align=center bgColor=#ffffff
border=0>
  <TR vAlign=top bgColor=#ffffff>
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD></TR>
  <TR vAlign=top bgColor=#ffffff>
    <TD>&nbsp;</TD>
    <TD colSpan=2>pSivida Limited</TD></TR>
  <TR vAlign=top bgColor=#ffffff>
    <TD>&nbsp;<BR>&nbsp;</TD>
    <TD>&nbsp;<BR>&nbsp;</TD>
    <TD>&nbsp;<BR>&nbsp;</TD></TR>
  <TR vAlign=top bgColor=#ffffff>
    <TD></TD>
    <TD>By:&nbsp;&nbsp;</TD>
    <TD><U>/s/ Aaron
      Finlay&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      </U></TD></TR>
  <TR vAlign=top bgColor=#ffffff>
    <TD colSpan=2>&nbsp;</TD>
    <TD align=left>Aaron Finlay</TD></TR>
  <TR vAlign=top bgColor=#ffffff>
    <TD colSpan=2>&nbsp;</TD>
    <TD><EM>Chief Financial Officer and Company
Secretary</EM></TD></TR></TABLE></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 207pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV id=PGBRK style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=FTR>
<DIV id=GLFTR style="WIDTH: 100%" align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV>
<DIV id=PN style="PAGE-BREAK-AFTER: always">
<DIV style="WIDTH: 100%; TEXT-ALIGN: center"><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt" face="Times New Roman"></FONT></DIV>
<DIV style="WIDTH: 100%; TEXT-ALIGN: center">
<HR color=#000000 noShade SIZE=2>
</DIV></DIV>
<DIV id=HDR>
<DIV id=GLHDR style="WIDTH: 100%" align=right><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV></DIV>
<DIV>&nbsp;</DIV>
<DIV>&nbsp;</DIV>
<DIV>&nbsp;</DIV>
<DIV>&nbsp;</DIV>
<DIV><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG><EM><U>EXHIBIT
INDEX</U></EM></STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><STRONG><EM><U><FONT face="Times New Roman"
size=2></FONT></U></EM></STRONG>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><STRONG><EM><U><FONT face="Times New Roman"
size=2></FONT></U></EM></STRONG>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><STRONG><EM><U><FONT face="Times New Roman"
size=2></FONT></U></EM></STRONG>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
  <TR>
    <TD vAlign=top align=left width="15%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=left><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>EXHIBIT
      99.1:</STRONG></FONT></DIV></TD>
    <TD vAlign=top align=left width="62%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=left><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      initiates R&amp;D collaboration with University of South
      Australia</FONT></DIV></TD></TR>
  <TR>
    <TD vAlign=top align=left width="15%">&nbsp;</TD>
    <TD vAlign=top align=left width="62%">&nbsp;</TD></TR></TABLE></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><BR></DIV>
<DIV>&nbsp;</DIV>
<DIV>&nbsp;</DIV>
<DIV>&nbsp;</DIV>
<DIV>&nbsp;</DIV>
<DIV>&nbsp;</DIV>
<DIV>&nbsp;</DIV>
<DIV>&nbsp;</DIV>
<DIV>&nbsp;</DIV>
<DIV>&nbsp;</DIV>
<DIV>&nbsp;</DIV>
<DIV>&nbsp;</DIV>
<DIV>&nbsp;</DIV>
<DIV>&nbsp;</DIV>
<DIV>&nbsp;</DIV>
<DIV>&nbsp;</DIV>
<DIV>&nbsp;</DIV>
<DIV>&nbsp;</DIV>
<DIV>&nbsp;</DIV>
<DIV>&nbsp;</DIV>
<DIV>&nbsp;</DIV>
<DIV>&nbsp;</DIV>
<DIV id=PGBRK style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=FTR>
<DIV id=GLFTR style="WIDTH: 100%" align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV>
<DIV id=PN style="PAGE-BREAK-AFTER: always">
<DIV style="WIDTH: 100%; TEXT-ALIGN: center"><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt" face="Times New Roman">2</FONT></DIV>
<DIV style="WIDTH: 100%; TEXT-ALIGN: center">
<HR color=#000000 noShade SIZE=2>
</DIV></DIV>
<DIV id=HDR>
<DIV id=GLHDR style="WIDTH: 100%" align=right><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV></DIV></BODY></HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v020379_ex99-1.htm
<TEXT>
<html>
  <head>
    <title>
      Unassociated Document
</title><!-- Licensed to: vintage-->
<!-- Document Created using EDGARIZER HTML 3.0.0.26435 -->
<!-- Copyright 2005 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div>&#160;</div>
    <div>
      <div align="center">
        <table bgcolor="#ffffff" cellpadding="0" cellspacing="0" width="100%">

            <tr bgcolor="#ffffff">
              <td width="50%">&#160;</td>
              <td width="50%">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><img src="logo.jpg" alt=""></div>
              </td>
            </tr>
            <tr bgcolor="#ffffff">
              <td width="50%">&#160;</td>
              <td width="50%">&#160;</td>
            </tr>
            <tr bgcolor="#ffffff">
              <td width="50%">&#160;</td>
              <td width="50%">&#160;</td>
            </tr>
            <tr bgcolor="#ffffff">
              <td width="50%"><strong>ASX/MEDIA RELEASE</strong>&#160;&#160;</td>
              <td width="50%">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;<strong>20<sup>th</sup>
                  June
                  2005</strong></div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;<strong>&#160;</strong>&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong><u>pSivida
      initiates R&amp;D collaboration with </u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong><u>University
      of South Australia </u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong><u>New
      R&amp;D collaboration to focus on delivery of biopharmaceuticals in
      BioSilicon&#8482;</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">Global
      nanotechnology company pSivida Limited (<strong>ASX:PSD,
      NASDAQ:PSDV, XETRA:PSI)</strong> announces today that it has entered into a
      research and development collaboration with the Ian Wark Research Institute
      (&#8220;The Wark&#8482;&#8221;) at the University of South Australia to evaluate the potential of
      its BioSilicon&#8482; platform for the delivery of protein- and peptide-based
      therapeutics.</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">Protein-
      and peptide-based drugs (or biopharmaceuticals),
      including antibodies, hormones and growth factors, already account for a
      substantial and increasing segment of the pharmaceutical market. A recent market
      report<sup>1 </sup>estimates global sales of biopharmaceuticals in 2004 at
      approximately US$48 billion, and these have been increasing at 19% over the
      past
      five years; this represents about 9% of the global pharmaceutical market, which
      is estimated at US$550 billion and which grew 7% in 2004, according to IMS
      Health.</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">Biopharmaceuticals
      are used to treat a broad spectrum of
      conditions, ranging from cancer to diabetes and from anaemia to osteoporosis.
      Furthermore, biopharmaceuticals account for more than one third of the
      industry&#8217;s development pipeline<sup>1</sup>. However, this class of drugs faces
      several problems with their use, which significantly impacts on their
      effectiveness, for example they cannot be easily administered orally, and they
      tend to be very susceptible to rapid degradation.</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">pSivida&#8217;s
      promising preliminary investigations using BioSilicon&#8482;
      have indicated its utility for the delivery of biopharmaceuticals, including
      its
      potential for the development of new controlled release formulations of existing
      marketed therapeutics. The collaboration with the Wark&#8482;, which is initially for
      a period of six months with the possibility of further extension, will
      investigate further this potential application of BioSilicon&#8482; and will form the
      basis of future R&amp;D programmes in this important area.</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">pSivida&#8217;s
      Managing Director, Gavin Rezos, said, &#8220;The Ian Wark
      Research Institute is one of the leading science and technology centres in
      Australia and I am very pleased that we have initiated this exciting R&amp;D
      project with them. The R&amp;D expertise and track record of the Wark&#8482; in the
      areas of nanotechnology, biomaterials and drug delivery means that we have
      an
      excellent opportunity to advance the development of our unique BioSilicon&#8482;
      platform as a potential solution to the current problems surrounding the
      delivery of biopharmaceuticals.&#8221;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">Professor
      Clive Prestidge, Head of the Bio and Polymer Interfaces
      research group at The Wark&#8482;, said, &#8220;One of our core philosophies is to establish
      links with companies at the leading edge of research in nano and biomaterials
      and we are very pleased and excited to be working with pSivida on this R&amp;D
      programme.&#8221;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><strong>-ENDS-</strong></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div align="center">
      <table bgcolor="#ffffff" cellpadding="0" cellspacing="0" width="100%">

          <tr bgcolor="#ffffff">
            <td width="33.33%"><strong>Released by:</strong></td>
            <td width="33.33%">&#160;</td>
            <td width="33.33%">&#160;</td>
          </tr>
          <tr bgcolor="#ffffff">
            <td width="33.33%">&#160;</td>
            <td width="33.33%">&#160;</td>
            <td width="33.33%">&#160;</td>
          </tr>
          <tr bgcolor="#ffffff">
            <td width="33.33%"><strong>In Australia:</strong>&#160;</td>
            <td width="33.33%"><strong>In US:</strong></td>
            <td width="33.33%">&#160;</td>
          </tr>
          <tr bgcolor="#ffffff">
            <td width="33.33%">Josh Mann</td>
            <td width="33.33%">Beverly Jedynak</td>
            <td width="33.33%">&#160;</td>
          </tr>
          <tr bgcolor="#ffffff">
            <td width="33.33%">Investor Relations</td>
            <td width="33.33%">President</td>
            <td width="33.33%">&#160;</td>
          </tr>
          <tr bgcolor="#ffffff">
            <td width="33.33%">pSivida Limited&#160;</td>
            <td width="33.33%">Martin E. Janis &amp; Company, Inc.</td>
            <td width="33.33%">&#160;</td>
          </tr>
          <tr bgcolor="#ffffff">
            <td width="33.33%">Tel: + 61 8 9226 5099</td>
            <td width="33.33%">Tel: 312-943-1100 ext. 12</td>
            <td width="33.33%">&#160;</td>
          </tr>
          <tr bgcolor="#ffffff">
            <td width="33.33%"><u>joshuamann@psivida.com</u></td>
            <td width="33.33%"><u>bjedynak@janispr.com</u></td>
            <td width="33.33%">&#160;</td>
          </tr>

      </table>
    </div>
    <div align="center">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <div>
        <hr style="COLOR: #000000" align="left" noshade size="1" width="10%">
      </div>
    </div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup><em>1</em></sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>&#160;</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Research
      &amp; Markets (May 2005) Biopharmaceuticals - Current Market Dynamics and Future
      Outlook</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>&#160;</em></font></div>
    <div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;&#160;&#160;&#160;&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: #000000" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;&#160;&#160;&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><strong>NOTES
      TO EDITORS:</strong></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><strong>pSivida
      Limited</strong></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">pSivida
      is a global nanotechnology company committed to the
      biomedical sector and the development of products in healthcare. The company&#8217;s
      focus is the development and commercialisation of a modified form of silicon
      (porosified or nano-structured silicon) known as BioSilicon&#8482;. As a new and
      exciting biocompatible material, BioSilicon&#8482; offers multiple potential
      applications across the high growth healthcare sector, including controlled
      release drug delivery, targeted cancer therapies (including brachytherapy and
      localized chemotherapy), tissue engineering and orthopedics. Potential
      diagnostics applications are being developed through its subsidiary AION
      Diagnostics Limited. </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">pSivida
      owns the intellectual property rights to BioSilicon&#8482; for
      use in or on humans and animals. The IP portfolio consists of 26 patent
      families, with 30 granted patents and over 80 patent applications. The core
      patent, which recognises BioSilicon&#8482; as a biomaterial was granted in the UK in
      2000 and in the US in 2001. </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">pSivida
      is listed on NASDAQ (<strong>PSDV</strong>), the
      Australian Stock Exchange (<strong>PSD</strong>) and in Germany on the Frankfurt
      Stock Exchange on the XETRA system (<strong>German</strong>&#160;<strong>Symbol:
      PSI. Securities Code (WKN) 358705</strong>). pSivida&#8217;s shares also trade in the
      United Kingdom on the OFEX International Market Service (IMS) under the ticker
      symbol <strong>PSD</strong>.</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">The
      Company&#8217;s strategic partner and largest shareholder is the
      QinetiQ group, the largest science and technology company in Europe. QinetiQ
      is
      the former UK government Defence Evaluation Research Agency and was instrumental
      in discovering BioSilicon&#8482;. pSivida enjoys a strong relationship with QinetiQ
      having access to its cutting edge research and development facilities. For
      more
      information on QinetiQ visit <u>www.qinetiq.com</u>.</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">For
      more information visit <u>www.psivida.com</u></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><strong>The
      Ian Wark Research Institute, University of South
      Australia</strong></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">The
      Ian Wark Research Institute is a premier research facility of
      the University of South Australia, incorporating the Australian Research Council
      Special Research Centre for Particle and Material Interfaces. The Wark<sup>TM
</sup>conducts a blend of fundamental and applied research on materials
      of all
      kinds, with an underlying emphasis on surface phenomena. Since its inception
      just over 10 years ago, The Wark has created an enviable record of research
      performance and practical problem-solving for industry partners. A core activity
      within the institute is the research undertaken by the Bio and Polymer
      Interfaces Sector which specialises in biomaterials; applying advanced surface
      chemistry techniques to the study of drug delivery and formulation, interfacial
      phenomena in pharmaceutical processing and manufacturing, the structure of
      biological cells, membranes and tissues and the adsorption of proteins and
      other
      biological compounds at bio-interfaces.</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">For
      more information, visit <u>www.unisa.edu.au/iwri</u></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">This
      document contains forward-looking statements that involve
      risks and uncertainties. Although we believe that the expectations reflected
      in
      such forward-looking statements are reasonable at this time, we can give no
      assurance that such expectations will prove to be correct. Given these
      uncertainties, readers are cautioned not to place undue reliance on such
      forward-looking statements. Actual results could differ materially from those
      anticipated in these forward-looking statements due to many important factors
      including: our failure to develop applications for BioSilicon<sup>TM</sup> due
      to regulatory, scientific or other issues. Other reasons are contained in
      cautionary statements in the Registration Statement on Form 20-F filed with
      the
      U.S. Securities and Exchange Commission, including, without limitation, under
      Item&#160;3.D, "Risk Factors" therein. We do not undertake to update any
      oral or
      written forward-looking statements that may be made by or on behalf of
      pSivida.</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: #000000" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@$`2`!(``#_X0N817AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````4````<@$R``(````4````AH=I``0````!````G````,@```!(````
M`0```$@````!061O8F4@4&AO=&]S:&]P(#<N,``R,#`U.C`V.C(P(#`P.C`S
M.C0P``````.@`0`#`````?__``"@`@`$`````0```/*@`P`$`````0```$D`
M````````!@$#``,````!``8```$:``4````!```!%@$;``4````!```!'@$H
M``,````!``(```(!``0````!```!)@("``0````!```*:@````````!(````
M`0```$@````!_]C_X``02D9)1@`!`@$`2`!(``#_[0`,061O8F5?0TT``O_N
M``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43
M$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-
M$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#/_``!$(`"<`@`,!(@`"$0$#$0'_W0`$``C_Q`$_```!
M!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!``````````$`
M`@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R
M!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5
MXF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7
MI[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q
M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S
MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_
MV@`,`P$``A$#$0`_`/54DEA=2MMPNHBRESH<WU'-+B09+MS-I_-]JK<WS0Y:
M`R2CQ0XA&5'6/%^E7Z28QLT[JR>M_6?H_0PQF;:795\#&PJ6FS(M<?;6RC'9
M[OTC_P!&Q[]E7J?X15NH9U(SGXV+EO=D,:VW)QP\S6VS^8EO^#W[7_HT3T*Z
M,+]IAH?FW-:W[0]K2]H)VPRW;ZFWW_G/4/\`I$#-FQ2QD?=X>YDE8/HX>./"
M/ZR>#0&]W.;1];NM-=E]3R_^;?2MA/V/'V.RRP@[K,O/M:YF$]FWU&_9V?S;
M]EOIVUHG^+^[/R.DY-^1D796$_+M_9=V4=U[\4$-KMMM,.?ZEGJ>GOK]G_$^
MEZ<ATG)ZQBMQKK7U]/O<[[>6V.%EU;2-N"-?T562[?\`;+V?I?L[/LO_`&HL
MMIW;[\#I.`;;2S%P<2L#00RNMHVM:UE8]K&_1:QBM<OF.;%#*8\'&.(1N_3^
MBM(H^3926%_SX^J8<P'J=/OVZR=K=[O3;ZK]NRAV[Z?K>GZ?T[/8K75LZZES
M**';'.&YSM.#[&-#G^UON0YGF(<OB.6=D"A4=92E+:,4Q'$:#II+(INZGCYK
M*+]U['QN@;@`[V^H+`UFW8[Z>]6+3_E.L?:MF@_5_=KH_P`]BBASHG&QCE&7
MN##*&3AQ2B9?I>J7K_P$\/CTO1OI+/P^O]'SLV_`Q,IMN5B[O7J`(+=CO0L^
MDT-]EHV+(ZM]8>C]7Z%U`=,ZPW%..*3;FL%GZ(66#TOYOTK/UCTK*OT3U;6$
MZ/3I+`Z#U##Z?]5*<[.ZH,[&J]0V=2?OATW6,:W],ZR[V/=]F8U<W]<?KF;;
M<!WU=ZD16?5;DBH"=P=B>EZC+Z]_T+;=B5H,@!9\/Q?0TEG]4Z_T?I!K'4LN
MO'=<8K8XDN='+A6S<_8W_2?04^E]:Z7U>M]O3<AF2RIVRS;(+71NAS7AKOHI
M+KZ/_]#U5<[U?J73K>NT='IWW]3])UME=+-XJ8T>HQ^8_>QM+;/H5;O4_GO^
M%K]2U]:^OM^K_1;<\5^MD$MIQ*()]2ZP[:J_;[O^$=_(8A?5/ZOV=(Q+,G.?
M]HZSU$B[J>2?SK-=M+`WV>EC[_39Z?\`X'_-5Q<Q@AGQ2Q9!<9?R!2"0;#EX
MW3L3I[;!30^O)R;7WYEUQ+K+7.(<S=;8!9Z=+7;*JO\`!_\`"6V66+1=9=E8
ME&'34\MKC>\#0D`C3Z+-O]=Z#]:NM8>+D8^'4'YG42UQKP,<;K2":PVR[_!X
MF/\`O9&1_P""*_\`5ZCJ?V5N7U*YOJ6,#:\.C^9I8/S/4.Y^5E?Z?(W>E_W'
MHJ_PV/#DLL^=YG'DRGAE"`E.HC)GQQ$-O^A+*R<0$10_L;^%C#&QFU=]7'XG
MW'Q67]=O_$IU/_B#^4+<6']=O_$IU/\`X@_E"VHPCCQB$1481X8^46&6H+YW
MU#IF!7]1L+J-=+&9M^;D5WW`>^QCFY;378?SF?H*7;/^#_XQ>BXV-CY/1NFL
MLN;7D?9J16YQ!+MS&2US7'])O7`X'U8^M/6^C8U>+D4OZ4ZV^RFJU^WT+=UN
M/:][6TV6W;M]UE6R_9^FL_1U+T6WHH&)C4X[_P!)B5,I:Y^FYC`&MW%@]MC8
MW^U0\Y"4L$XC&,]@7BD>'CC^EPG]_P#<8^6!%2^4&$`#IT08V3EX&2W%R#-9
M($$S`=[6OJ?^YN_-1<C_`)<I^`_ZFQ*GIF9;DLNS7@AD&)W$[?<UOT6L:S<K
M%N%<_J5>4"WTV`2#.[0/'A_+6;CP<R<48F.3VX<SBGBCEUS0P1^;C_JQ;)(O
MIL;KN^<=?NM^K?UNZJ^MSJV]0Q[O0+9W;LVO]#M<S;Z7^5L1_P"E_P`'O_MH
M_3\!N/\`XLNHY8YS;VEIG_!TWTX5/]7^CNL_ZZNA^NOU0S^NY6-E].MIJNIJ
MLJM]<N`();9CD>DRQWZ-_J_]NJ]U'ZMVV_4]OU>PWL%E=-%+++9#3Z+JG/>_
MTVN_G/2=^8MIIF$OUHK3AEP?]5]4_P#GQ>,Z@YX_Q9])(<0!G6%S>SH?GN:'
M?U;`RS^PJ?UEZ5@=/P/J[;B5"NW,PP_*LDDVO:[$M;;;^];OR\C])_+]/^;J
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MJ'6.B]9OS^H9-.4+JK*W6L+_`%'O?:R[UK&V-V_I&L=ZOZ7^<_D(]5THR.2,
MN&JGN.'U1X?F/Z3_`/_1Z;Z[69F/U+I.7]C'4L%ED,QCD-QXS0^J[I]U6_:^
M[(_1WUU5?I=_Z2M-9C?XP>NGT\BRGZMX+M'MQW>OEF/I;;V?H:_4^DQ]3Z[*
MO^$7@J22.K]#]"Z7]3<2BW&Z5?1<^L@9MK;VV7.?+O?FVUOW>HY_J_3]GT_3
MK6SA4X%1L^QEI)CU-KMW&[;N]SOY2^7TE6'W3W]/:^\_X'O_`"_^&?(N]5=:
M_!^JE3ZMC]/R>FY%'4W-;@V,C(<YYJ:&_P`JX.K]/_/7S"DK*'Z;Z)B]*Q.G
M,HZ0YK\)KGECF6&T;BYSK?TKG6;OTN_\]7U\JI)(%4*VZ4_522^54DDOU4DO
ME5))3]5)+Y5224_522^54DE/_]G_[1!24&AO=&]S:&]P(#,N,``X0DE-!"4`
M`````!``````````````````````.$))30/M```````0`$@````!``$`2```
M``$``3A"24T$)@``````#@`````````````_@```.$))300-```````$````
M>#A"24T$&0``````!````!XX0DE-`_,```````D```````````$`.$))300*
M```````!```X0DE-)Q````````H``0`````````!.$))30/U``````!(`"]F
M9@`!`&QF9@`&```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&
M```````!`#4````!`"T````&```````!.$))30/X``````!P``#_________
M____________________`^@`````_____________________________P/H
M`````/____________________________\#Z`````#_________________
M____________`^@``#A"24T$`````````@`!.$))300"```````$`````#A"
M24T$"```````$`````$```)````"0``````X0DE-!!X```````0`````.$))
M300:``````-)````!@``````````````20```/(````*`%4`;@!T`&D`=`!L
M`&4`9``M`#$````!``````````````````````````$``````````````/(`
M``!)``````````````````````$`````````````````````````$`````$`
M``````!N=6QL`````@````9B;W5N9'-/8FIC`````0```````%)C=#$````$
M`````%1O<"!L;VYG``````````!,969T;&]N9P``````````0G1O;6QO;F<`
M``!)`````%)G:'1L;VYG````\@````9S;&EC97-6;$QS`````4]B:F,````!
M```````%<VQI8V4````2````!W-L:6-E241L;VYG``````````=G<F]U<$E$
M;&]N9P`````````&;W)I9VEN96YU;0````Q%4VQI8V5/<FEG:6X````-875T
M;T=E;F5R871E9`````!4>7!E96YU;0````I%4VQI8V54>7!E`````$EM9R``
M```&8F]U;F1S3V)J8P````$```````!28W0Q````!`````!4;W`@;&]N9P``
M````````3&5F=&QO;F<``````````$)T;VUL;VYG````20````!29VAT;&]N
M9P```/(````#=7)L5$585`````$```````!N=6QL5$585`````$```````!-
M<V=E5$585`````$```````9A;'1486=415A4`````0``````#F-E;&Q497AT
M27-(5$U,8F]O;`$````(8V5L;%1E>'1415A4`````0``````"6AO<GI!;&EG
M;F5N=6T````/15-L:6-E2&]R>D%L:6=N````!V1E9F%U;'0````)=F5R=$%L
M:6=N96YU;0````]%4VQI8V5697)T06QI9VX````'9&5F875L=`````MB9T-O
M;&]R5'EP965N=6T````115-L:6-E0D=#;VQO<E1Y<&4`````3F]N90````ET
M;W!/=71S971L;VYG``````````IL969T3W5T<V5T;&]N9P`````````,8F]T
M=&]M3W5T<V5T;&]N9P`````````+<FEG:'1/=71S971L;VYG```````X0DE-
M!!$```````$!`#A"24T$%```````!`````(X0DE-!`P`````"H8````!````
M@````"<```&````Z@```"FH`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[0`,
M061O8F5?0TT``O_N``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+
M$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`"<`@`,!(@`"$0$#$0'_
MW0`$``C_Q`$_```!!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!
M`0$!``````````$``@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$
M(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F
M1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:F
MML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!
M46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD23
M5*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V
M)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`/54DEA=2MMPNHBRESH<WU'-+B09
M+MS-I_-]JK<WS0Y:`R2CQ0XA&5'6/%^E7Z28QLT[JR>M_6?H_0PQF;:795\#
M&PJ6FS(M<?;6RC'9[OTC_P!&Q[]E7J?X15NH9U(SGXV+EO=D,:VW)QP\S6VS
M^8EO^#W[7_HT3T*Z,+]IAH?FW-:W[0]K2]H)VPRW;ZFWW_G/4/\`I$#-FQ2Q
MD?=X>YDE8/HX>./"/ZR>#0&]W.;1];NM-=E]3R_^;?2MA/V/'V.RRP@[K,O/
MM:YF$]FWU&_9V?S;]EOIVUHG^+^[/R.DY-^1D796$_+M_9=V4=U[\4$-KMMM
M,.?ZEGJ>GOK]G_$^EZ<ATG)ZQBMQKK7U]/O<[[>6V.%EU;2-N"-?T562[?\`
M;+V?I?L[/LO_`&HLMIW;[\#I.`;;2S%P<2L#00RNMHVM:UE8]K&_1:QBM<OF
M.;%#*8\'&.(1N_3^BM(H^3926%_SX^J8<P'J=/OVZR=K=[O3;ZK]NRAV[Z?K
M>GZ?T[/8K75LZZES**';'.&YSM.#[&-#G^UON0YGF(<OB.6=D"A4=92E+:,4
MQ'$:#II+(INZGCYK*+]U['QN@;@`[V^H+`UFW8[Z>]6+3_E.L?:MF@_5_=KH
M_P`]BBASHG&QCE&7N##*&3AQ2B9?I>J7K_P$\/CTO1OI+/P^O]'SLV_`Q,IM
MN5B[O7J`(+=CO0L^DT-]EHV+(ZM]8>C]7Z%U`=,ZPW%..*3;FL%GZ(66#TOY
MOTK/UCTK*OT3U;6$Z/3I+`Z#U##Z?]5*<[.ZH,[&J]0V=2?OATW6,:W],ZR[
MV/=]F8U<W]<?KF;;<!WU=ZD16?5;DBH"=P=B>EZC+Z]_T+;=B5H,@!9\/Q?0
MTEG]4Z_T?I!K'4LNO'=<8K8XDN='+A6S<_8W_2?04^E]:Z7U>M]O3<AF2RIV
MRS;(+71NAS7AKOHI+KZ/_]#U5<[U?J73K>NT='IWW]3])UME=+-XJ8T>HQ^8
M_>QM+;/H5;O4_GO^%K]2U]:^OM^K_1;<\5^MD$MIQ*()]2ZP[:J_;[O^$=_(
M8A?5/ZOV=(Q+,G.?]HZSU$B[J>2?SK-=M+`WV>EC[_39Z?\`X'_-5Q<Q@AGQ
M2Q9!<9?R!2"0;#EXW3L3I[;!30^O)R;7WYEUQ+K+7.(<S=;8!9Z=+7;*JO\`
M!_\`"6V66+1=9=E8E&'34\MKC>\#0D`C3Z+-O]=Z#]:NM8>+D8^'4'YG42UQ
MKP,<;K2":PVR[_!XF/\`O9&1_P""*_\`5ZCJ?V5N7U*YOJ6,#:\.C^9I8/S/
M4.Y^5E?Z?(W>E_W'HJ_PV/#DLL^=YG'DRGAE"`E.HC)GQQ$-O^A+*R<0$10_
ML;^%C#&QFU=]7'XGW'Q67]=O_$IU/_B#^4+<6']=O_$IU/\`X@_E"VHPCCQB
M$1481X8^46&6H+YWU#IF!7]1L+J-=+&9M^;D5WW`>^QCFY;378?SF?H*7;/^
M#_XQ>BXV-CY/1NFLLN;7D?9J16YQ!+MS&2US7'])O7`X'U8^M/6^C8U>+D4O
MZ4ZV^RFJU^WT+=UN/:][6TV6W;M]UE6R_9^FL_1U+T6WHH&)C4X[_P!)B5,I
M:Y^FYC`&MW%@]MC8W^U0\Y"4L$XC&,]@7BD>'CC^EPG]_P#<8^6!%2^4&$`#
MIT08V3EX&2W%R#-9($$S`=[6OJ?^YN_-1<C_`)<I^`_ZFQ*GIF9;DLNS7@AD
M&)W$[?<UOT6L:S<K%N%<_J5>4"WTV`2#.[0/'A_+6;CP<R<48F.3VX<SBGBC
MEUS0P1^;C_JQ;)(OIL;KN^<=?NM^K?UNZJ^MSJV]0Q[O0+9W;LVO]#M<S;Z7
M^5L1_P"E_P`'O_MH_3\!N/\`XLNHY8YS;VEIG_!TWTX5/]7^CNL_ZZNA^NOU
M0S^NY6-E].MIJNIJLJM]<N`();9CD>DRQWZ-_J_]NJ]U'ZMVV_4]OU>PWL%E
M=-%+++9#3Z+JG/>_TVN_G/2=^8MIIF$OUHK3AEP?]5]4_P#GQ>,Z@YX_Q9])
M(<0!G6%S>SH?GN:'?U;`RS^PJ?UEZ5@=/P/J[;B5"NW,PP_*LDDVO:[$M;;;
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MIU.[T]GT/]&KGU1^J'6.B]9OS^H9-.4+JK*W6L+_`%'O?:R[UK&V-V_I&L=Z
MOZ7^<_D(]5THR.2,N&JGN.'U1X?F/Z3_`/_1Z;Z[69F/U+I.7]C'4L%ED,QC
MD-QXS0^J[I]U6_:^[(_1WUU5?I=_Z2M-9C?XP>NGT\BRGZMX+M'MQW>OEF/I
M;;V?H:_4^DQ]3Z[*O^$7@J22.K]#]"Z7]3<2BW&Z5?1<^L@9MK;VV7.?+O?F
MVUOW>HY_J_3]GT_3K6SA4X%1L^QEI)CU-KMW&[;N]SOY2^7TE6'W3W]/:^\_
MX'O_`"_^&?(N]5=:_!^JE3ZMC]/R>FY%'4W-;@V,C(<YYJ:&_P`JX.K]/_/7
MS"DK*'Z;Z)B]*Q.G,HZ0YK\)KGECF6&T;BYSK?TKG6;OTN_\]7U\JI)(%4*V
MZ4_522^54DDOU4DOE5))3]5)+Y5224_522^54DE/_]DX0DE-!"$``````%4`
M```!`0````\`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'`````3`$$`
M9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P`"``-P`N`#`````!`#A"24T$
M!@``````!P`!`````0$`_^$22&AT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"\`/#]X<&%C:V5T(&)E9VEN/2?ON[\G(&ED/2=7-4TP37!#96AI2'IR95-Z
M3E1C>FMC.60G/SX*/#]A9&]B92UX87`M9FEL=&5R<R!E<V,](D-2(C\^"CQX
M.GAA<&UE=&$@>&UL;G,Z>#TG861O8F4Z;G,Z;65T82\G('@Z>&%P=&L])UA-
M4"!T;V]L:VET(#(N."XR+3,S+"!F<F%M97=O<FL@,2XU)SX*/')D9CI21$8@
M>&UL;G,Z<F1F/2=H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S`R+S(R+7)D9BUS
M>6YT87@M;G,C)R!X;6QN<SII6#TG:'1T<#HO+VYS+F%D;V)E+F-O;2]I6"\Q
M+C`O)SX*"B`\<F1F.D1E<V-R:7!T:6]N(&%B;W5T/2=U=6ED.C,U9#,T.&4S
M+64Q-#`M,3%D.2TX,&-E+6$R.#8U,3<V,C,W.2<*("!X;6QN<SIX87!-33TG
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+VUM+R<^"B`@/'AA<$U-.D1O
M8W5M96YT240^861O8F4Z9&]C:60Z<&AO=&]S:&]P.C,U9#,T.&4Q+64Q-#`M
M,3%D.2TX,&-E+6$R.#8U,3<V,C,W.3PO>&%P34TZ1&]C=6UE;G1)1#X*(#PO
M<F1F.D1E<V-R:7!T:6]N/@H*/"]R9&8Z4D1&/@H\+W@Z>&%P;65T83X*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"CP_
M>'!A8VME="!E;F0])W<G/S[_[@`.061O8F4`9(`````!_]L`A``,"`@("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.%!0.#@X.%!$,#`P,#!$1#`P,
M#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!)`/(#`2(`
M`A$!`Q$!_]T`!``0_\0!/P```04!`0$!`0$``````````P`!`@0%!@<("0H+
M`0`!!0$!`0$!`0`````````!``(#!`4&!P@)"@L0``$$`0,"!`(%!P8(!0,,
M,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C
M<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E
M]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$``@(!`@0$`P0%!@<'!@4U`0`"
M$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#
M!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&
MEJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1`Q$`/P#U5))))2DDDDE*2222
M4I0NNJHJ??>]M5-32^RQY#6M:T;GO>]WM:QK5S/UK_Q@]'^KCG8LMR^IMV..
M&'[`UCM?4OR-EC*_T?O]%K;<I^^G]!Z5GK+G*?JS];_KK=5U#ZQ9#NF8+7`M
MP@Q[2'5'9ZF/@7DLH]5EF3MS<_[1E?N8OV7T4D&70"S_`"W='J7^-"NR]V']
M6NGW=6NV.<+0QX'#/3MIQ*ZWY>33O?\`I-_V*K]'_2?TOJ*AU3JW^-#I]!ZQ
MFBO$Q66UMLQVMQWL:-U53-U37WY#L;*LM]-_I]1?E,L]3^CT[%W72.@]'Z)2
MZGI>*S&:_6QPEUCS+GCU\BPOOOVNM?L]6Q_IKB_\8/4,KKG5L7ZG='&_*;8+
M<IS@6,:_T_5HW6.]ME.-19]LR?T-OZ7[!Z'Z?]$DLF)<)]1OIPZ>KH]A]6.M
M?MWH.'U4L]-^0PBU@B!96YU%_IPZS]#ZU5GH^_\`FEJ*OT_"JZ?@8V!07.IQ
M*:Z*W/(+BVMK:F%Y:&MW[6_NJPDR*22224I))))2DDDDE*22224I))))2DDD
MDE*22224I))))2DDDDE*22224__0]522224X/6L-M).1JX7.,DQ#7<Q^\[?#
MD;HW4'O>,:UQ>'`FIQDF1JZN?^IW(O7A.)7S_.CC^J]9."2,JD@D$6L$SKJ6
MM<-/WMRYKF)?<_B<?9N,)F''#]&0R_.S`<4-73ZACYE#'Y+,IY9ODURX0'.@
M;3N/T=RSCF98!/K6:?RS_>LO/^O0ZGU^OHG2*VY&`-QS,O:YTA@WLNQG,(K9
MB-R/1Q_M5OJ,RK+OU?\`P=U]Y_T3\"HOC43@YF,<4IP$X"<AQS/JE.?[TE8B
M)1O>C3T&%AY5+_4R,@VRTCT]2`21[MSG>7[BR>J9[\BQS`^*&G:T#AT'Z;MO
MT_<W]&NB)`!),`:DE<C$AL3Q^:85KXR?N^##R^(RC#(92G<I2E+AX?FE+]&7
M$C'J22RSNINZ/@T7],I^V]8ZF78W3L#<T!SP2ZW(M_FW_9L=E7JWO]FS^;LM
MJ]7UV6?J=]3,;ZN4V9-SSF=9S/=G9SR7.)<=[ZJG/]_I>I[['N_2Y-OZ6[_`
MU4Z^!B8K:L?*%+!D>@*_6VC?L=%KZ_4^GZ;[?TFS]]75K\EACAY;%"(`],92
M\9R'KDQR),B2I))>6XW^-7KK#3=F8F/D4/:=U6-78RPN-;W4#UK<BZNJO[1Z
M7K6OJ?LI5ECGDC`@2-<6@?4DEY17_C2^LEK'&H=.>\08;7:X#GVN(R_^FO0_
MJWU['^L'2J^H4L-+R37D8[B'.JM;_.5.<WZ7YME3_P#"4656[&)(AEA,D1.H
MW&S'/ZM;7<ZC&#?9H^PZ^[^1K^9_+_/5(=5S^U\D=MK/_(JL\/EX?/J2[=/.
MZ3N_Z2VQ3@YV!Z>*&M+&_HQIN8[^7])S=SF?I/\`2+E\>7G.>RYS#F)890N6
M/`)&!E_4`CP_+^E)M$1B!I?BRZ;U+[7NJM:&W-&[VSM+9Y'.W;*EU4Y`QV^A
MOW[Q/IS,0[]Q`PND647UWV6`N9/L:#&H+/IDCQ_T:L]2RK<6AME0:7%X:=P)
M$0X_FEO@M2$LY^'S^^\6*0!!G&CD]OT\,_1^FLTXQPZH.D'++KOM'J1#-GJ;
MOY>[;O6DJ'2\Z_+-HM#1Z>V-H(^EN_><[]U<%UC_`!C?6;!S^H8U>/B1AWW5
MU5V4VEY8QSOLY?&2SW74^E;_`#?O]16?AYA]UQ^W.62'JJ<_GEZY?,QYLD8&
MY^FR`^F)+&^LG7CTOZMW]9P!7ED-J^S$NFIQO?713;OJGU*?T[;OT?\`.L_P
MG^$7._5/ZY_6+K?7JNGWLPVXPIMOR',9:RS:S94P4[K[V;_7R*=V_P#P/JJV
M@Y(B48$^J5T/)S_K=9]:Q]8\T8`ZI]D!K]+[,W)-7\U5O]/[./1_G-^_9_A%
MWGU?^T_L'IOVOU/M7V2CU_6W>IZGIL]7UO4_2>KO_G/4]^]<A]9OKUUWI77<
MOI^(S$-%!K##;78Y_OJJN=O<S)J9].QW^#78]%S+<_H^!G7!K;<K&IOL#`0T
M.L8VQ^P.+W;-SOWDNK%BX./)PRE(WZ@=H_W6ZN+_`,87U@ZQT?(Z;7TW(^SM
MR&9+K@&5OW&LXHJ_GF6;=OK6?16)F_XT.M.RLBSI]>&WIP>?LK[J[7O=4/H9
M%CO7Q-GK?SWI^C^A9^C>L7KGUJR/K*S`?DU5MOPADLMMQS-+Q:[&=1L8]]EM
M5K64/]:MWJ?Z3UOTOI5);FYB'!,1GZHZ:=_[SZ#_`(O^L]2ZOTO,OZE=]HMI
MRW55NVL9#!3C6[8I96W^<NL74+B_\5?_`"-U#_P^[_VWPU6^LW^,;*P^HV].
MZ+CTV?97[,C+R-SF%[=XNHIQZG4N=Z5GIL?>[(^GZU7H_P"$29(Y(QPPE.5>
MF.I\GO4EY8[_`!F?6G;[*\`N`X--T$_^QGM7??5KZPXOUAZ:,VACJGL>:<FA
MTS7:T->]C7[6>K7LLKLJM;].JS_!V;ZF)./-CR6(2NOHZJ2223(__]'U5)))
M)37SZ3?B65-;N)@AL[9@AT;B'?NKF\C'J-1!;6^BP;2PNKN:Z>SV-W-=6]O[
M[-BP_KS]9<_JW5!]3^B$-;>\8^3<TEQM>1^EQIHWOJP<1O\`RK;_`#GZ.[&_
MP=WK]7T7ZH=.Z1TFGIS'OL?4)?D3M+GN)LM<RGWTTUN>YVRK_!_^"+,^)_#C
MS-9,9K-``1L\,:CZOFX92XDX\FI'0;GQ<_HW2.@]$Z%;A]-#A?86.O?>0Z^P
MA_Z-K[6MJ;;70SVTMJ9LKK_X2RQ)_P!$_`K1SNDC&I?>RTN8W;#'-UU(9]-I
M;^]^XL]QAI/@%@_%9<R<T/O48QR1QB/I-C)'CG^L_P`)GQB('IVMVNH]2QAC
M655/%C[&EOMU:`[1SG/;[?HK*QL0WN:-H=OT8/4:TB)W$UNWV?\`06DSH+)/
MJWN<.P8T-_ZKU5>QL+&Q1^B9[H@O.KC_`&OE]%:LN1YOG,\<G-1CAQP'"(0D
M)2K_`,<8^*,14=4E5;:JF5-DMK:&@GF`-JFDDML```#0#0,:EX5T"BG(S^E4
M9%;;J;,C&;96\!S7--E>YKV.]KFN7NJ\,^K1`ZIT>3'ZSBC[[*DNH:G.?-A_
MOO7?XT\6IN9TG(96QKO2R*GO``<6M.,^FLN_T=>Z[8W\SU%H_P"*L1T7/\\]
MQ_\`9?#5+_&K81?TFN-'-RG3_5.(/^_JY_BN<[]A]0V@%PSG0"8!/V?$/.J1
M*8W]\G_<_P"]>AZCTDVO-^+`L,FRLZ!Q_>;^[8LG]+1>>:KZS![$?^2;_P!!
M7QUV]SP[TV"J1+1+G;?SX=N8W=_85[J=>/?@OM<1^C:7U6`CF/;M=_PGT5SV
M?EN4YSW>8Y/(<>7%ZY_H0G_7C^Y_?;X,HT)#0HNF]3=D.&/>`+0V6O&F^/I>
MW]]/UO\`HC/^,'Y'K*PB\9E!9.[>WCP.EG_@>]:O6_Z(S_C!^1Z=AYO)S'PK
MF/=)E+&.#C_>CZ:_PE&($Q2'H/TLCX,_]&+S[_&+@'$^M+\@;_3ZE17=N=&W
MU:OU2]E3@T?0H9A/>U_^E7H/0?I9'P9_Z,6#_C1P/5Z5B=18R7X5^RRR8VTY
M`])WLGW^IF-P/HM]3_K7K+0^#_[@P_X?_I2;7YV'%#(/"_\`%]3S'5^JMS/J
M+]7,&T-=?5=:)8/8&=/%O3F>H'/>YN0]N3B7_P#;EGZ/]$MS_%3@4.;U+JWM
M=:;&X+3M!<UM36Y-NV[Z6VY^56VRK_NI_P!M^>MK?7=;;9:33])C"X[6$AC<
MA^TGT_TC<?'WV?\`!?\`!KV7ZC83\+ZI]-JL=N?95]H?[=FTY+G9KJMA+_YG
M[1Z7]A:#6P3]W+Q_NPC'_"EZI/GWUY_\5G4/C3_YXH7<U>K_`.-NST7FNW]B
MCTW@D%KOLOL>'-]S=KEPWUY_\5G4/C3_`.>*%W%=@J_Q;-L=)#.BAQCF!BRE
MU1R]^[S%;W_WSYS]6NF8W4OK!TSI^2T'%==NLJAI:YM%=N6RE[+&O8ZE]F/6
MRUG^A71?XT<+$IZKT_+IJ;7D9=5XR;&B#9Z)Q&T&W]]]3+7L:_Z>SV+%^IUU
M=/UKZ4^UP8PVO9N<8&ZRB^FIO_7+K*ZF?\)8N@_QK?TOH_\`Q>7_`-5@H+,?
M^XY^9=#_`!5_\C=0_P##[O\`VWPUBYO^+O!Z52W+Z_U^K[`VP.R?5I=6^\`^
MO?0+FYKKGY&777;_`#++,BS\Q:G^+;*HPOJWU;,R7>GCXV79;<^"=K&8V)98
M[:P.>[:QOYJX'*S.H]?ZG1E9;F/ZIU&VO'Q_4W-JJ-KME-%;?TKJ,>CU/?M_
M26^]]GJ7V(LQE$8L-QXY$1X(_P!;A=KZU=1^IV<:6?5_IIQKL>WW9E5#<6JR
MIU9]2MU4TY%OZ;T=OK8GL]-_I/\`3_G=S_%36UM_5W@0Y[<7=YQ]J6=]:OJE
MTGZN=(PRS(?D]4OO`?;:_:7UMJ=Z_H8=9;2RAE_HN^A;=5ZWIV9*T_\`%5_.
M=5^&-^7*2_@L!G][CQ5?#^CM3Z`DDDDW7__2]57'?XQOK:.B8`Z?BV;,_.8X
MFUK]KJ*)%=F5[?TOK6;O1PO^&_2?]I_37777545/NN>VJJII?98\AK6M:-SW
MO>[VM8UJ\XQ<:OZP?XS1EV/L=@UX]'5,)M@L`LJ95B_8_1E]?ITMS\J[)=[=
MGVFBVJW_``J2V=U0W.E]G>_Q?_5/]A].^UYM3&]4RF@.@$NHHAIJP/4?])S'
M?I<E[-GJ7^S]*S'HL76)+#Z[]<^@]#<ZG)N-^8V)PL>++A.S^<;N;7C^RUMO
MZU;1ZE?\UO25I&/8!T.K_P#)]OQ9_P!6Q>?=:^MN-BW?LSIC/VAU6[<RNFN"
MQCP=A^TV;AL]/WO?7_P?Z;[/_.H&7U;ZU_7C&-;6CI'0KQ8T/K)L-I:&5OI=
M;^A?F;;M_P#,?9,+^<KMMS;:_16QTKH/2^D5/KP*15ZL>H\G<]Q`V;GN_P"G
MLK;51O?9Z--*Y[XR>6',1R9#[N2$!`<N-!O*?'FG^[Z_YOYV;$9$:"A?S?\`
M>N]T?ZOYK,T=8Z_E-ZCU5K2W&#&>GCXC+/=?3@U?2<]SOT3\Z[]:NQJZ:O\`
M2^IO+/Z?U-^7;Z+ZPQP9N+@Z02"UOT=OM^E^\M!;F#F,6?&,F*7%`Z71CJ/[
MRP@@T5)))*5"EX!AX5G4&8N#6&%^4:J6BR0R;"RMN]S-SV?2^FUOL7OZ\,^K
M#FGJO1P"#^LXO_GRI+J&ISF^+^\FR.B?6NS.V9W3NHY&?[*=]OJ9+8=[V,9U
M%S[<1M#'7>_]9KKK_2>JO3/J-T')Z'T(4YNF;E6NR<FL.#VUN>&55T,>QK/Y
MK'II99_.?I_5V6^FNA229H88PD9`DREUD>+3LX_4.DVFXW8HWBPDOKD`AQUW
MM+R/:Y9[</)+@&X]DDP/81S_`"G`-74)+)YCX'R^7(<@E+'Q&Y1C7#_@_NM@
M9"!6[E],Z8^E_P!HR-+!(96#.W\W<[;^<Y'ZICW9&.UE+=S@\$B0-(=^\KJ2
MMQY#!'EI<K&XXY#U$?SDB?T^+]Y'$;XG-Z3B9&,ZXW,V[PS;J#,;Y^B3^\F^
MLO2OVQT'.Z:`#9?2[T)<6`7-_2XEA?7[OT>2RJQ::2EY;EX<OACA@28PNC+Y
MO5+C_1X42/$;/5\BK_Q?_67(?33E8;J<:ZRMF4]MM&]E+GM;E.;^DM;O91ZG
MYMB]=224S%APQQ`B-ZF]7SCZU_5+ZP]0^L.9FX>)ZN/<:_3?ZE39VU55N]ME
MC7_38Y=KT;`=5]7<'IV?4TN9AU8^30_:]I(J;5=4_P"G78SZ3/W%I))*AAC"
M4Y`FYFS;XOU#ZH?6'HM[<7[+D93*7`XN;A5V/W"LM?3=^J^K?AWU_H_YS9^F
M_H]EU?Z1'9]3OKMU`5]0R<>ZPO9M8W+O:_(V0RVLV_:;7/HKW6V[,;U/4]3U
M_7II_P`)["DDQGE8'B%R`F;X;]-_W7DOJ7]7,O$Z#U+IG6L?8S.R+-U6\'?3
M91CXS_?CO=LW>G:SZ?J+S[)^K?UFZ?<,?*Z?E.OI+7UY6$RRYCBQY]/(HR,)
MI?2_?5ZS66_9\BOV?HU[<DDNER\)1A$DCVZX9`^H4^/#ZE_77/%/4[L>RU]@
M%99FY&_+;5M=?6[]8M>VBCU'['T/O^T^M_VE_P`(NP_Q?]!ZOT>WJ/[2Q_0;
M>VCT7;V/W%AR/5$4OLV[/4K^DNQ225'EX"8R7(R`K4\2DDDDF9__T_1?K#BW
MYO0.IX>,WU,C)Q+ZJ62!N>^M]=;=SRUC=SW?G+S3I/U]^L?2,6OHEE%;[L5C
M,;'IR*+:\ICB&NPZ[L=CV?:OU?\`0U554T67^RWUK/\`#>MI),>7BH</%U^3
MA_[M\Q?9_C.^LSV-;7;TS&8_:YPW=.KEK7/]1^]U_6;-_J>E^B_5-_\`Q5MB
MUN@?XK>EX;:[>LO&?<V'#%8#7B-=^C?K3/J9>RUEGOR7>C;79_0UW"22V/!8
MXKXNGN=_ZO\`D^+^XI))))F4DDDDI22222E))))*4DDDDI22222E))))*4DD
>DDI22222E))))*4DDDDI22222E))))*4DDDDI__9
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
